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Summary
 
The present study was designed to investigate the effect of bacterial lipopolysaccharide (LPS)
on C–C chemokine receptors (CCR) expressed in human mononuclear phagocytes. LPS caused a
rapid and drastic reduction of CCR2 mRNA levels, which binds MCP-1 and -3. CCR1 and
CCR5 mRNAs were also reduced, though to a lesser extent, whereas CXCR2 was unaffected.
The rate of nuclear transcription of CCR2 was not affected by LPS, whereas the mRNA half
life was reduced from 1.5 h to 45 min. As expected, LPS-induced inhibition of CCR2 mRNA
expression was associated with a reduction of both MCP-1 binding and chemotactic respon-
siveness. The capacity to inhibit CCR2 expression in monocytes was shared by other microbial
agents and cytokines (inactivated 
 
Streptococci
 
, 
 
Propionibacterium acnes
 
, and to a lesser extent, IL-1
and TNF-
 
a
 
). In contrast, IL-2 augmented CCR2 expression and MCP-1 itself had no effect.
These results suggest that, regulation of receptor expression in addition to agonist production is
likely a crucial point in the regulation of the chemokine system.
 
T
 
he recruitment of leukocytes from the blood compart-
ment represents one of the characteristic elements of
the inflammatory process (1). Locally produced chemotac-
tic agents are believed to play a crucial role in the activation
of cells during the multistep process of leukocyte accumu-
lation in tissues (2, 3).
In the past few years a new superfamily of chemotactic
cytokines, named chemokines, has been described. The hall-
mark of this family are four conserved cysteine residues (4–7).
According to the relative position of the first two cysteines
it is possible to distinguish two main families: the C-X-C
(or 
 
a
 
) chemokines, which are primarily active on neutro-
phils, but show some action on T lymphocytes (4–7); and
the C–C (or 
 
b
 
) chemokines that exert their action on mul-
tiple leukocytes populations, including monocytes, basophils,
eosinophils, T lymphocytes, NK and dendritic cells (4–10).
Recently, a third type of protein (the C or 
 
g
 
 chemokines)
was described, which is active on T lymphocytes and NK
cells. This protein is characterized by the absence of the
first and third cysteines, but shows overall sequence identity
with C–C chemokines (11, 12).
Chemokines, as well as classical chemotactic agonists, such
as formylated peptides (of which FMLP is the prototype)
and C5a, bind to and activate a family of rhodopsin-like
GTP-binding protein-coupled seven-transmembrane do-
main receptors (13–15). Five receptors for C–C chemo-
kines, now named CCR1 through 5, have been identified
and cloned (14–17). In addition to recognizing chemokines,
usually with some degree of promiscuity, C–C chemokine
receptors act as coreceptors for primate lentiviruses such as
HIV-1, HIV-2, and SIV (18–22). In particular CCR5 is a
major determinant of the interaction of HIV-1 with mono-
nuclear phagocytes (17–22).
MCP-1 is a prototypic C–C chemokine active on mono-
nuclear phagocytes, basophils, T cells and NK cells (4, 8,
10). It is produced by a variety of cell types, including en-
dothelial cells and cells of the monocyte-macrophage lin-
eage, in response to diverse inflammatory signals, typically
IL-1, TNF-
 
a
 
, and bacterial LPS. MCP-1 interacts with
CCR2, of which two isoforms have been cloned and
termed A and B (23). In monocytes and NK cells CCR2 is
expressed predominantly as B isoform, with vanishingly
low levels of A transcripts (23a). In addition to MCP-1,
CCR2 recognizes MCP-3 (24–26). Although the regula-
tion of chemokine production has been extensively investi-
gated, little is known as to whether microenvironmental sig-
nals may affect the chemokine system by modulating
receptor expression (27, 28). This lack of information, and
previous observations demonstrating that LPS modulates
the in vitro replication as well as the establishment of pro-
ductive HIV-1 infection in cultured macrophages (29–31),
prompted us to investigate the possible effect of LPS on the
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expression of C–C chemokine receptors. Here, we report
that LPS rapidly downregulates CCR2 and, to a lesser ex-
tent, CCR1 and CCR5 expression in monocytes by acting
on mRNA stability.
 
Materials and Methods
 
Cells.
 
Human monocytes were separated from peripheral
blood of human healthy donors by Percoll gradient centrifugation
(32). Monocytes (
 
>
 
98% pure as assessed by morphology) were
resuspended at 10
 
7
 
/ml in RPMI 1640 supplemented with 10% of
fetal bovine serum, 2 mM glutamine and antibiotics. All reagents
contained less than 0.125 EU/ml of endotoxin as checked by
Limulus Amebocyte Lysate assay (Microbiological Associates, Walk-
erville, MD).
 
Cytokines and Reagents.
 
Human recombinant IL-1
 
b
 
 was a gift
of Dr. Boraschi (Dompè, L’Aquila, Italy); TNF
 
a
 
, from BASF/Knoll
(Ludwighafen, Germany); IL-2, from Eurocetus (Milan, Italy); LPS
(
 
E. coli
 
 055:B5) from Difco (Detroit, MI); Actinomycin D (ActD)
from Sigma Chem. Co. (St. Louis, MO); MCP-1, from Pepro-
Tech Inc. (Rocky Hill, NC); inactivated Streptococci (OK432)
from Chugai Pharmaceutical Co., Ltd. (Osaka, Japan); Candida Al-
bicans from American Type Culture Collection (Rockville, MD);
Glucan from Dr. N.R. Di Luzio (Tulane University School of
Medicine, New Orleans, LA); P. Acnes from Wellcome Biotec-
nology Ltd. (Beckenham, UK).
 
Migration Assay.
 
Cell migration was evaluated using a
chemotaxis microchamber technique (33) as previously described
(32). 27 
 
m
 
l of chemoattractant solution or control medium (RPMI
1640 with 1% FCS) were added to the lower wells of a chemotaxis
chamber (Neuroprobe, Pleasanton, CA). A polycarbonate filter
(5-
 
m
 
m pore size; Neuroprobe) was layered onto the wells, cov-
ered with a silicon gasket and with the top plate. 50 
 
m
 
l of cell sus-
pension (1.5 
 
3
 
 10
 
6
 
/ml monocytes in PBMC) were seeded in the
upper chamber. The chamber was incubated at 37
 
8
 
C in air with
5% CO
 
2 
 
for 90 min. At the end of the incubation, filters were re-
moved, stained with Diff-Quik (Baxter s.p.a., Rome, Italy) and
five high power oil-immersion fields were counted.
 
Receptor Binding Assays.
 
Competition for the binding of [
 
125
 
I]
MCP-1 (specific activity 2,200 Ci/mmol; Du Pont de Nemours,
Bad Homburg, Germany) to Percoll-purified human monocytes was
carried out as described previously (26). Monocytes (1 
 
3
 
 10
 
7
 
/ml)
in binding medium (RPMI 1640 with 10 mg/ml bovine serum
albumin; Sigma, Milan, Italy) were incubated with 1 nM of la-
beled cytokine in the presence of different concentrations of un-
labeled cytokine at 4
 
8
 
C for 2 h. At the end of the incubation, cells
were pelleted through a cushion of silicon oil by micro-centrifu-
gation. The radioactivity present in the tip of the tubes and in the
supernatants was evaluated by using a gamma counter. IC
 
50
 
 values
for the different ligands were calculated using “ALLFIT” program
as previously described (26).
 
Northern Blot Analysis.
 
Total RNA was isolated by the guanid-
ium isothiocyanate method as previously described (34). 15 
 
m
 
g of
total RNA from each sample were electrophoresed under denatur-
ing conditions, blotted onto Nytran membranes (Schleicher &
Schuell Inc., Keene, NH), and cross-linked by UV irradiation.
cDNAs were labeled by random priming and 
 
a
 
-[
 
32
 
P]dCTP.
CCR2B cDNA was obtained by PCR amplification of the re-
ported sequence (23, 35). CCR1 and CCR5 cDNAs were ob-
tained as previously described (16). The IL-8RB (CXCR2)
cDNA clone (27) was kindly donated by Dr. Ji Ming Wang (Na-
tional Cancer Institute, Frederick, MD).
 
Nuclear Run-off Experiments.
 
Nuclear run-off experiments were
performed essentially as described (34). Nuclei were isolated after
4 h of stimulation. Then
 
 
 
60 
 
m
 
l of 5
 
3
 
 run-off buffer (25 mM Tris-
HCl, pH 8, 12.5 mM MgCl
 
2
 
, 750 mM KCl, and 1.25 mM each
of ATP, CTP, and GTP), 2 
 
m
 
l of RNase inihibitors 1 U/
 
m
 
l (Perkin
Elmer Cetus), 200 
 
m
 
Ci of 
 
a
 
-[
 
32
 
P]UTP 3,000 Ci/mmol (Amer-
sham) were added to 220 
 
m
 
l of nuclei suspension and incubated at
30
 
8
 
C for 30 min. Elongated transcripts were then isolated using
the guanidine/cesium procedure,with 50 
 
m
 
g of yeast tRNA added
as carrier. The RNA pellet was resuspended in 180 
 
m
 
l of ice-cold
TNE (NaCl 100 mM, 10 mM Tris-HCl, pH 8, 1 mM EDTA,
pH 8) and denaturated adding 20 
 
m
 
l of 2N NaOH on ice for 10
min. The solution was neutralized by the addition of 200 
 
m
 
l of
0.48 M Hepes. RNA was precipitated by adding 880 
 
m
 
l of etha-
nol; the pellet was resuspended in 100 
 
m
 
l of H
 
2
 
O and radioactiv-
ity checked with 
 
b
 
-counter. The RNA solution was denaturated
at 65
 
8
 
C for 5 min and hybridized at 42
 
8
 
C for 48 h to 5 
 
m
 
g of
denatured DNA immobilized on nitrocellulose filters in a few milli-
liters of hybridization solution (200 mM NaHPO
 
4
 
, pH 7.2, 1mM
EDTA, pH 8, SDS 7%; deionized formamide 45%; 
 
E. coli
 
 tRNA
250 mg/ml). In a given experiment, each filter was hybridized
with the same number of cpm. Filters were then washed one or
two times at 37
 
8
 
C for 20–30 min in 40 mM NaHPO
 
4
 
-SDS 1%
and exposed for autoradiography.
 
Results
 
Inhibition of CCR2 mRNA Expression by LPS.
 
Human
monocytes express high levels of CCR1, CCR2, and CCR5
transcripts (Fig. 1). CCR3 and 4 were undetectable by
Northern analysis under these conditions (not shown). Us-
ing either a CCR2A or a CCR2B cDNA–specific probes,
we detected a single 3.4-kb transcript, as previously re-
ported (23, 23a). As shown in Fig. 1, LPS induced a dose-
dependent inhibition of the steady state level of CCR2
mRNA after 4 h, with a dramatic inhibition already at 1
ng/ml (Fig. 1 
 
A
 
) and virtually complete suppression at in-
creasing concentrations, 10 and 100 ng/ml. Removal of
the LPS after 4 h resulted in a gradual and complete resto-
ration of the CCR2 mRNA level in 24 h (data not shown).
Similar results were obtained by using the CCR2A cDNA–
specific probe (data not shown). Likewise, but to a lesser
extent, a significant LPS-dependent reduction of the CCR1
(Fig. 1 
 
B
 
) and CCR5 (
 
C
 
) mRNA levels was observed. In
contrast, the mRNA level of CXCR2 was unaffected (Fig.
1 
 
D
 
).
 
LPS Destabilizes CCR2 mRNA.
 
Having established that
low concentrations of LPS cause a rapid and drastic reduc-
tion of CCR2, subsequent work was focused mainly on
this receptor. To investigate the mechanism of LPS action,
we estimated its effects on both mRNA stability and gene
transcription (Fig. 2). ActD (1 
 
m
 
g/ml) was added to fresh
human monocytes in the presence or absence of 100 ng/ml
of LPS and total RNA was extracted at different times as
indicated. In the presence of ActD the estimated half-life of
the transcript was about 1.5 h (Fig. 2, lanes 
 
2–6
 
), while
cotreatment with ActD and LPS (lanes 
 
7–11
 
) considerably
shortened this time (
 
z
 
45 min). To evaluate the effects of
LPS on gene transcription, we used nuclear run-off analysis
(Fig. 2 
 
C
 
). In agreement with published results (34), LPS 
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was able to induce MCP-1 gene transcription. In contrast,
LPS did not induce appreciable variations on the transcrip-
tion rate of the CCR2, CCR1, and CCR5 genes. Taken
together, these data indicate that the inhibitory action of
LPS on CCR2 gene expression is posttranscriptional and
suggest similarities of the mechanisms controlling gene ex-
pression of the three 
 
b
 
 chemokine receptors studied here.
 
LPS Downregulates MCP-1 Binding and Chemotaxis.
 
MCP-1
is a high-affinity ligand for the CCR2 receptor (23). There-
fore we measured the [
 
125
 
I]MCP-1 binding in untreated and
LPS-treated fresh human monocytes. As shown in Fig. 3 
 
A
 
, a
significant time-dependent inhibition of the [
 
125
 
I]MCP-1
binding was observed after LPS treatment, which resulted
in 60% of reduction after 5 h. Likewise, LPS treatment in-
duced a strong decrease in the number of monocytes mi-
grating in response to MCP-1 (Fig. 3 
 
B
 
). Thus, in human
monocytes the LPS-mediated inhibition of CCR2 expres-
sion results in a marked reduction of both binding and mi-
gratory response to MCP-1, with the latter being much
more sensitive to the action of LPS. A stronger inhibition
of chemotaxis compared to receptor binding was previ-
ously described also for IL-8 (27).
 
Effect of Other Microbial Agents and Cytokines on CCR2
Expression.
 
Having established that LPS rapidly inhibits
CCR2 expression, we wanted to investigate whether other
microbial agents or components and cytokines affected this
chemokine receptor. We tested agents (e.g., inactivated
 
Streptococci
 
, 
 
Propionibacterium acnes
 
, 
 
Candida albicans
 
, 
 
glucan
 
)
known to affect various functions of monocytes, including
chemokine production (36, 37). As shown in Fig. 4 
 
A
 
, CCR2
gene expression was completely suppressed either by treat-
ment with inactivated 
 
Streptococci
 
 or 
 
P. acnes
 
. Furthermore,
the CCR2 mRNA level was also partially affected by 
 
Glu-
Figure 1. Effect of LPS on the
CCR2 (A), CCR1 (B), CCR5
(C) and CXCR2 (D) mRNA
expression: dose-response analy-
sis. E shows the ethidium bro-
mide stained ribosomal RNA. A
is representative of four different
donors. B and C are representa-
tive of two different donors. To-
tal RNA was purified from fresh
human monocytes incubated for
4 h as indicated.
Figure 2. Destabilization of CCR2 mRNA by LPS. (A) effect of LPS
(100 ng/ml) on the CCR2B mRNA transcript stability. Total RNA was
purified from fresh human monocytes incubated for 4 h as indicated. B
shows the ethidium bromide stained ribosomal RNA. (C) Nuclear run-
off analysis of the MCP-1, CCR1, CCR2, and CCR5 genes. Fresh hu-
man monocytes were incubated with 100 ng/ml of LPS for different peri-
ods as indicated.
Figure 3. Inhibition by LPS of
MCP-1 binding and chemotaxis.
(A) Binding. fresh human mono-
cytes were incubated for 1–5 h
in the presence or absence of 100
ng/ml of LPS before [125I]MCP-1
binding assay. Results are ex-
pressed as percent of bound on
total counts. (B) Chemotaxis.
Fresh human monocytes were
stimulated with 100 ng/ml of
LPS and chemotactic response to
MCP-1 (100 ng/ml) was mea-
sured after different periods as
indicated.972 Lipopolysaccharide and C-C Chemokine Receptors
can, but not by C. albicans. Among cytokines (Fig. 4 C), we
found that IL-2 stimulates CCR2 expression thus extend-
ing to monocytes recent results with T lymphocytes and NK
cells (23, 28, 35). In contrast, TNF-a and IL-1b reduced
CCR2 expression and MCP-1 itself had no effect (not
shown).
Discussion
The results presented here show that LPS causes a drastic
and rapid downregulation of the expression of CCR2, a re-
ceptor for MCP-1 and -3. The ED50 of LPS was z1 ng/ml
and half-maximal effect was reached with an optimal dose
in z45 min. Inhibition of MCP-1 receptor expression was
functionally relevant since LPS-treated monocytes showed
a reduced capacity to bind and to respond to MCP-1
chemotactically. Two isoforms of CCR2 (A and B) have
been cloned (23). Monocytes and activated NK cells ex-
press predominantly a 3.5-kb mRNA encoding the B form,
with low levels of A transcripts (23, 35). LPS reduced ex-
pression of both isoforms (Fig. 1 and data not shown). More-
over LPS also inhibited expression of CCR1 and CCR5,
though to a lesser variable extent than CCR2. The action
of LPS on C–C chemokine receptors was specific in that
CXCR2 was unaffected. It was previously reported that
LPS does not affect the FMLP receptor in neutrophils (7, 27).
Little information is available on regulation of expression
of chemokine receptors. In neutrophils, LPS and TNF-a
were reported to inhibit the expression of IL-8 receptors,
while G-CSF increased it (27). IL-2 was shown to induce
CCR2 in T lymphocytes and NK cells (23a, 28, 35), an
observation confirmed here for monocytes. Interestingly,
CCR2 induction in T cells was a slow process, requiring
four days of exposure to the cytokine (28). The results re-
ported here show a dramatic, rapid and differential down-
regulation of chemokine receptors by LPS in monocytes.
LPS did not inhibit the rate of nuclear transcription of
CCR2, but did reduce the mRNA half life from 1.5 h to
45 min. This result is in agreement with the observation
that the 39-untranslated region of the mRNAs of several rho-
dopsin family members, contain AU-rich elements, which
correlate with highly regulated short-lived mRNAs (38,
39). Chemokine receptors play a central role in HIV-1 in-
fection (40, 41). In particular CCR5, CCR1, and CCR3
have been involved as coreceptors for macrophage-tropic
HIV-1 strains (18–22). The finding that LPS and cytokines
reduce expression of these coreceptors may to some extent
explain the bidirectional effects of these agents on HIV in-
fection (e.g., 29–31). More in general, they point to the
feasibility of targeting C–C chemokine receptor expres-
sion, as an alternative to occupancy, to inhibit infection.
LPS and bacterial agents used in the present study, as well
as IL-1 and TNF, are potent inducers of various chemokines
in monocytes including MCP-1 and -3 (10). The results
reported here show that these agents have divergent actions
on C–C chemokine production and receptor expression in
monocytes. Regulation of CCR chemokine receptor ex-
pression, in addition to agonist production, is likely a cru-
cial point for regulation of the chemokine system. We
speculate that the divergent effect of certain proinflamma-
tory signals on agonist versus receptor expression may serve
to retain mononuclear phagocytes at sites of inflammation,
to prevent their reverse transmigration (42), and, possibly,
to limit excessive recruitment.
Figure 4. Effects of microbial products (A) and cytokines (C) on
CCR2 mRNA expression. B and D show the ethidium bromide stained
ribosomal RNA of A and C, respectively. Total RNA was purified from
fresh human monocytes incubated for 4 h as indicated. (A) lane 1, un-
treated; lane 2, LPS 100 ng/ml; lane 3, inactivated Streptococci OK432
(0.015 KE/ml); lane 4, P. acnes (10 mg/ml); lane 5, C. albicans (100 mg/
ml); lane 6, Glucan (100 mg/ml). (C) lane 1, untreated; lane 2, IL-2 (1,000
U/ml); lane 3, LPS (100 ng/ml); lane 4, TNF-a (500 U/ml); lane 5, IL-1-b
(20 ng/ml).
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